• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Tracon Pharmaceuticals Inc (NQ: TCON )

    1.430 UNCHANGED
    Last Price Updated: 4:00 PM EDT, Jun 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Tracon Pharmaceuticals Inc

    < Previous 1 2 Next >
    TRACON Pharmaceuticals Announces it Will Wind Down Operations
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON Pharmaceuticals Announces Reverse Stock Split
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
    Full ENVASARC accrual expected in Q4 and final data expected in mid-2024 
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma
    Collection of Award Extends Cash Runway into early 2024 and Past Expected Full Accrual of the ENVASARC Pivotal Trial 
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual Conference
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON Pharmaceuticals Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 10, 2023
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    Runway Growth Finance Corp. Provides First Quarter 2023 Portfolio Update
    From Runway Growth Finance Corp.
    Via GlobeNewswire
    TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    TRACON to Report Fourth Quarter and Year-End 2022 Financial Results and Provide Corporate Update on March 8, 2023
    From TRACON Pharmaceuticals, Inc.
    Via GlobeNewswire
    Runway Growth Finance Corp. Provides Fourth Quarter 2022 Portfolio Update
    From Runway Growth Finance Corp.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.